Used in the treatment of hypercholesterolemia and prevention of cardiovascular events by targeting PCSK9, a protein that regulates LDL cholesterol levels in the blood. By inhibiting PCSK9, this antibody increases the liver’s ability to remove LDL cholesterol from the bloodstream, significantly lowering LDL-C levels in patients who do not achieve target levels with statins alone. It is administered via subcutaneous injection and is particularly beneficial for patients with familial hypercholesterolemia or a history of atherosclerotic cardiovascular disease. Its use supports intensive lipid-lowering strategies in high-risk populations.